SignalXSignalX

OLMA Olema Pharmaceuticals, Inc.

Q3 2025 10-Q
Filed: Nov 10, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Olema Pharmaceuticals, Inc. Overview

Olema Pharmaceuticals, Inc. (OLMA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 10, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New regulatory risk: Loan Agreement amendments in 2025 lowered interest to 6.0% minimum, extended draw period to Jan 15, 2026, increasing debt service complexity
  • • Material update financial risk: Net loss widened to $42.2M in Q3 2025 from $34.6M in Q3 2024, reflecting escalating R&D and operational expenses
+3 more insights

Get deeper insights on Olema Pharmaceuticals, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.